Drug Formulary Committee: Minutes of September 22, 2015 Public Meeting

Members in attendance
Stacey Ness, Pharm.D., Al Heaton, RPh., Margaret Artz, RPh, Ph.D., Stuart Williams, J.D., William Korchik, M.D.

DHS staff present
Sara Drake, RPh., MPH, MBA

Others in attendance
Nina Bandali, Pharm.D.

Report of the Chair
No updates

Approval of the minutes
Minutes from the March meeting were not be provided but members are to review and send any comments to DHS.

Old Business
The Committee discussed the DHS criteria for Synagis for the 2015-2016 RSV season. The committee voted unanimously to recommend the state adopt the AAP 2014 guidelines for the use of Synagis.

New Business

Class Review: COPD Inhalers
The committee discussed the inhalers available for treatment of COPD. The committee recommended unanimously that the department create two pathways for inhaler criteria – a COPD pathway and an Asthma pathway. The committee recommended the department manage the category based on cost while ensuring that at least one long acting beta agonist (LABA) combination product is available.

New Drugs for Continued PA
The committee discussed Belsomra (suvorexant)
The committee recommended to the department that Belsomra remain on PA by a unanimous vote.

The committee discussed Entresto (sacubitril/valsartan)
The committee recommended to the department that Entresto remain on PA by a unanimous vote. The committee recommend the department require a trial of a therapeutic dose of an ACE or ARB prior to approving Entresto. The committee requests the department bring additional information about the PA requests received to a future meeting.

The committee discussed Rexulti (brexpiprazole).
The committee recommended to the department that Rexulti remain on PA by a unanimous vote. The committee recommended criteria for depression requiring a trial and failure of two preferred SSRIs and another new generation antidepressant. The committee also recommended the PA ensure the patient will continue on a concurrent antidepressant while on Rexulti.

The committee discussed Savaysa (edoxaban tosylate)
The Department recommended that Savaysa remain on PA by a unanimous vote.

The committee discussed Movantik (naloxegol)
The committee recommended to the department that Movantik remain on PA by a unanimous vote. Recommended criteria include a trial of senna and a preferred osmotic laxative.

The committee discussed Soolantra (invermectin)
The committee recommended to the department that Soolantra remain on PA by a unanimous vote.

The committee discussed Lemtrada (alemtuzumab injection)
The committee recommended to the department that Lemtrada remain on PA by a unanimous vote. The committee recommended that the drug be kept to on-label use.

The committee discussed Evekeo (amphetamine sulfate)
The committee recommended to the department that Evekeo remain on PA by a unanimous vote. The committee recommended the criteria include a trial and failure of at least two preferred stimulant agents.

The committee discussed Corlanor (ivabradine)
The committee recommended to the department that Corlanor remain on PA by a unanimous vote. The committee recommended criteria including use of an ACE/ARB, diuretic, and mineralocorticoid antagonist.

**New Specialty Drugs for Continued PA**

The committee discussed Afrezza (human insulin, inhaled)
The committee recommended to the department that Afrezza remain on PA by a unanimous vote. Recommended criteria include: no history of smoking or chronic lung disease; patients with type 1 diabetes must be using basal insulin; patients must have tried prandial insulin for 90 days to ensure they can tolerate short acting insulin.

The committee discussed Orkambi (lumacaftor-ivacaftor)
The committee recommended to the department that Orkambi remain on PA by a unanimous vote. The committee recommended the drug be discussed again at the next meeting when more research or guidelines may be available for this drug.

The committee discussed Mircera (epoetin beta)
The committee recommended to the department that PA be removed for Mircera

The committee discussed Lynparza (olaparib)
The committee recommended to the department that Lynparza remain on PA by a unanimous vote.

The committee discussed Ibrance (palbociclib)
The committee recommended to the department that Ibrance remain on PA by unanimous vote. The committee recommended PA criteria to ensure the drug is used according to the FDA-approved label and in
accordance with NCCN guidelines. The committee recommended initial approval be limited to three months.

The committee discussed Cosentyx (secukinumab). The committee recommended to the department that Cosentyx remain on PA by unanimous vote. The committee recommended that Cosentyx be included in tier 2 of the immunomodulatory criteria.

The committee discussed Lenvima (lenvatinib)
The committee recommended to the department that Lenvima remain on PA by a unanimous vote. The committee recommended that the criteria include that the patient’s cancer be refractory to TSH suppressive hormone therapy.

The committee discussed Jadenu (Deferasirox)
The committee recommended to the department that Jadenu remain on PA by a unanimous vote. The committee recommend that the department apply similar PA criteria and requirements for Jadenu and Exjade.

The committee discussed Natpara (parathyroid hormone). The committee recommended to the department that Natpara remain on PA by a unanimous vote.

The committee discussed Daklinza (daclatasvir). The committee recommended to the department that Daklinza remain on PA by unanimous vote and be subject to the department’s current Hepatitis C criteria. The committee recommended Daklinza be a preferred agent for Hepatitis C Genotype 3.

The committee discussed Technivie (ombitasvir/paritaprevir/ritonavir). The committee recommended to the department that Technivie remain on PA by a unanimous vote and be subject to the department’s current Hepatitis C criteria. The committee recommended Technivie be a preferred agent for genotype 4 with the exception of patients with cirrhosis.

**Adjournment**
The meeting was adjourned at 8:55 pm CST.